Slide 1: Conference call presentation 9M 2024/25
Conference call presentation 9M 2024/25 Making life easier Strive25: Sustainable Growth Leadership Fikria, User, Continence Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Lars Rasmussen Anders Lonning-Skovgaard Dorthe Rønnau Allan Rasmussen Interim President and CEO EVP, CFO EVP, People & Culture EVP, Operations Since 2025 With Coloplast since 2006 With Coloplast since 2022 With Coloplast since 1992 Chronic Care Acute Care New
Slide 4: Q3 2024/25 financial result
NEW IMAGE Q3 2024/25 financial result Otto: add picture with Peristeen Light Update Update picture picture Organic Reported Adjusted ROIC growth EBIT margin 7% 28% * * 15% ** Update picture *before special items **after tax and before special items. Adjusted for extraordinary tax impact from the tra
Slide 5: Two proposed rules announced by the US CMS recently
Two proposed rules announced by the US CMS recently – competitive bidding for Chronic Care and fixed payment for skin substitutes Chronic Care Biologics Proposal • Proposed rule on Competitive Bidding for chronic care • Proposed fixed payment of $125/cm² for all skin categories substitute products i
Slide 6: 9M organic growth of 7% with broad-based contribution, except for Interventional Urology
9M organic growth of 7% with broad-based contribution, except for Interventional Urology which was impacted by the product recall 9M 2024/25 revenue by business area 9M 2024/25 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth S
Slide 7: 9M reported revenue grew 4%, with ~1%-point detraction from divested operations and currencies
9M reported revenue grew 4%, with ~1%-point detraction from both divested operations and currencies 9M 2024/25 Revenue development (mDKK) 9M 2024/25 highlights • Reported revenue increased by DKK 836 million or 4% vs. last year. • Organic growth was 7% or DKK 1,325 million, driven by: +836 mDKK • Br
Slide 8: Reported EBIT margin of 27% in 9M
Reported EBIT margin of 27%1 in 9M, driven by a higher level of distribution costs, partly offset by a lower level of administration cost 9M 2024/25 EBIT margin development before special items (%) 9M 2024/25 highlights • Gross margin was 68%, on par with last year. • Positive impact from a favourab
Slide 9: Adjusted FCF was DKK 3,327 million in 9M, with a FCF-to-sales ratio of 16%
Adjusted FCF was DKK 3,327 million in 9M, with a FCF-to-sales ratio of 16% FCF development1 9M 2024/25 highlights • Free cash flow for 9M 2024/25 was an inflow of DKK 3,519 million, 90 93 compared to an outflow of DKK 186 million last year. Last year’s FCF was 84 81 83 77 impacted by the tax payment
Slide 10: Organic growth and EBIT margin expectations for FY 2024/25 unchanged
Organic growth and EBIT margin* expectations for FY 2024/25 unchanged, reported revenue growth now expected at 3-4% Organic revenue growth Around 7% Reported revenue growth in DKK 3-4% Reported EBIT margin* 27-28% Effective tax rate** Around 40% (Ordinary tax rate) (Around 22%) Capital expenditures
Slide 11: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding